Literature DB >> 15313944

Beneficial effects of chronic pharmacological manipulation of beta-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy.

Ismayil Ahmet1, Melissa Krawczyk, Phillip Heller, Chanil Moon, Edward G Lakatta, Mark I Talan.   

Abstract

BACKGROUND: Studies in isolated cardiac myocytes have demonstrated that signaling via specific beta1-adrenergic receptor subtypes (beta1ARs) promotes but that signaling via beta2ARs protects from cell death. We hypothesized that prolonged beta(2)AR stimulation or beta1AR blockade would each protect myocytes from death and thereby ameliorate cardiac remodeling in chronic heart failure. METHODS AND
RESULTS: A large myocardial infarction (MI) induced in rats by coronary artery ligation resulted in a dilated cardiomyopathy (DCM) characterized by infarct expansion and a progressive increase in left ventricular (LV) end-diastolic volume, accompanied by a reduction in ejection fraction (EF), as assessed by repeated echocardiography. Pressure-volume analysis at 8 weeks after ligation showed that diastolic stiffness (Eed) and arterial elastance (Ea) were increased, end-systolic elastance (Ees) was decreased, and arterioventricular (AV) coupling (Ea/Ees) had deteriorated. Apoptosis was present in both peri-infarct and remote myocardium. Chronic (6-week) administration of the beta2AR agonists fenoterol or zinterol, starting at 2 weeks after MI, reduced the extent of LV dilation, infarct expansion, and EF decline. The beta1AR blocker metoprolol did not affect the former and preserved EF to a lesser extent than did the beta2AR agonists. At 8 weeks after ligation, apoptosis was reduced by all drugs but to a greater extent by beta2AR agonists than by the beta1AR blocker. Both beta2AR agonists and the beta1AR blocker improved AV coupling, the former mainly by reducing Ea and the latter mainly by increasing Ees. Only the beta2AR agonists reduced the Eed and the MI size by reducing infarct expansion.
CONCLUSIONS: These results provide proof of concept for the efficacy of chronic beta2AR stimulation in this DCM model.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15313944     DOI: 10.1161/01.CIR.0000139844.15045.F9

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  52 in total

Review 1.  β-Adrenergic receptor subtype signaling in heart: from bench to bedside.

Authors:  Anthony Yiu Ho Woo; Rui-ping Xiao
Journal:  Acta Pharmacol Sin       Date:  2012-01-30       Impact factor: 6.150

Review 2.  Calcium cycling proteins and their association with heart failure.

Authors:  L Hadri; R J Hajjar
Journal:  Clin Pharmacol Ther       Date:  2011-08-10       Impact factor: 6.875

3.  The 27-kDa heat shock protein confers cytoprotective effects through a beta 2-adrenergic receptor agonist-initiated complex with beta-arrestin.

Authors:  Lalida Rojanathammanee; Erin B Harmon; Laurel A Grisanti; Piyarat Govitrapong; Manuchair Ebadi; Bryon D Grove; Masaru Miyagi; James E Porter
Journal:  Mol Pharmacol       Date:  2009-01-27       Impact factor: 4.436

4.  Adenylyl cyclase type VI increases Akt activity and phospholamban phosphorylation in cardiac myocytes.

Authors:  Mei Hua Gao; Tong Tang; Tracy Guo; Atsushi Miyanohara; Toshitaka Yajima; Kersi Pestonjamasp; James R Feramisco; H Kirk Hammond
Journal:  J Biol Chem       Date:  2008-10-05       Impact factor: 5.157

Review 5.  Advances in receptor conformation research: the quest for functionally selective conformations focusing on the β2-adrenoceptor.

Authors:  Anthony Yiu-Ho Woo; Ying Song; Weizhong Zhu; Rui-Ping Xiao
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

6.  Pharmacological stimulation of beta2-adrenergic receptors (beta2AR) enhances therapeutic effectiveness of beta1AR blockade in rodent dilated ischemic cardiomyopathy.

Authors:  Ismayil Ahmet; Edward G Lakatta; Mark I Talan
Journal:  Heart Fail Rev       Date:  2005-12       Impact factor: 4.214

7.  Ventricular-arterial uncoupling in heart failure with preserved ejection fraction after myocardial infarction in dogs - invasive versus echocardiographic evaluation.

Authors:  Myrielle Mathieu; Bachar El Oumeiri; Karim Touihri; Ielham Hadad; Maryam Mahmoudabady; Philippe Thoma; Thierry Metens; Jozef Bartunek; Guy R Heyndrickx; Serge Brimioulle; Robert Naeije; Kathleen Mc Entee
Journal:  BMC Cardiovasc Disord       Date:  2010-06-29       Impact factor: 2.298

8.  Future g protein-coupled receptor targets for treatment of heart failure.

Authors:  Giuseppe Rengo; Anastasios Lymperopoulos; Walter J Koch
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-08

9.  Blueberry-enriched diet protects rat heart from ischemic damage.

Authors:  Ismayil Ahmet; Edward Spangler; Barbara Shukitt-Hale; Magdalena Juhaszova; Steven J Sollott; James A Joseph; Donald K Ingram; Mark Talan
Journal:  PLoS One       Date:  2009-06-18       Impact factor: 3.240

10.  Effects of Astragaloside IV on heart failure in rats.

Authors:  Zhuanyou Zhao; Weiting Wang; Fang Wang; Kerui Zhao; Yingmei Han; Weiren Xu; Lida Tang
Journal:  Chin Med       Date:  2009-04-02       Impact factor: 5.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.